Blood-based biomarkers have the potential to revolutionize clinical practice and clinical trials in Alzheimer disease (AD). However, to date, this “holy grail” opportunity has not been realized owing to a broad range of issues, including the lack of a clearly defined context of use (COU), lack of standardization of methods, and numerous failures at replication. Recently, however, a shift in the paradigm has occurred, with my colleagues and I proposing specific COUs for blood-based biomarkers along with potential paradigms for advancing from discovery to clinic and potential acceptable standards.1,2
Tobago and Pittsburgh Friendship nearly 30 years later
Dr. Caterina Rosano met with Secretary of Health, Wellness and Social Protection, Dr. Faith Brebnor to discuss Advance Dementia and Alzheimer's Research in Tobago. The Tobago Health Study, a project focused on assessing cognitive aging in women of African ancestry,...
